Carr Patricia 4
4 · Jazz Pharmaceuticals plc · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Jazz (JAZZ) Chief Accounting Officer Patricia Carr Sells Shares, Receives RSUs
What Happened
- Patricia Carr, Senior Vice President and Chief Accounting Officer at Jazz Pharmaceuticals (JAZZ), disposed of 2,370 ordinary shares in two open-market sales (1,253 shares on 2026-02-26 and 1,117 shares on 2026-02-27) for aggregate proceeds of $456,465. She also received a grant of 2,223 restricted stock units (RSUs) on 2026-02-26 (reported at $0.00 because they are contingent awards that convert to ordinary shares upon vesting).
- The sales were open-market transactions; the RSUs are a standard equity award rather than an immediate cash purchase — they vest over four years and will convert to shares only as they vest.
Key Details
- Transaction dates and prices:
- 2026-02-26: Sold 1,253 shares at a weighted average price of $194.11 for $243,222.
- 2026-02-27: Sold 1,117 shares at $190.91 for $213,243.
- 2026-02-26: Awarded 2,223 RSUs (contingent rights to one share each; reported at $0.00).
- Total proceeds from sales: $456,465.
- Vesting of RSUs (footnote): Grants under the 2011 Equity Incentive Plan vest in equal annual installments over four years beginning from the vesting commencement date of March 5, 2026 (1/4 on the first anniversary, then equal annual installments over the next three years).
- Sales used to satisfy tax withholding (footnote): Some shares were sold to cover tax obligations arising from prior RSU vesting.
- Reporting details: Sales reported with weighted-average pricing; one set of sales was executed in multiple transactions at prices ranging from $193.73 to $194.41 (detailed breakdown available on request). Filing date (2026-03-02) is within the Form 4 two-business-day reporting window for the Feb 26–27 transactions (timely).
Context
- These actions combine a routine equity award (RSUs) with open-market sales that include shares sold to satisfy tax-withholding obligations. Awards do not equal immediate shares until vesting; sales are commonly routine and do not necessarily signal a change in sentiment.
- No option exercises, gifts, or 10% owner transactions were involved. The filing is factual and does not state motivation.
Insider Transaction Report
Form 4
Carr Patricia
SVP, Chief Accounting Officer
Transactions
- Award
Ordinary Shares
[F1]2026-02-26+2,223→ 11,605 total - Sale
Ordinary Shares
[F2][F3]2026-02-26$194.11/sh−1,253$243,222→ 10,352 total - Sale
Ordinary Shares
2026-02-27$190.91/sh−1,117$213,243→ 9,235 total
Footnotes (3)
- [F1]These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
- [F2]Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- [F3]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.7300 to $194.4100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Signature
By: /s/Paz Dizon, as attorney in fact For: Patricia Carr|2026-03-02